General
Preferred name
ZOMEPIRAC
Synonyms
ZOMEPIRAC SODIUM ()
MCN-2783-21-98 ()
Zomax ()
McN-2783-21-98 ()
Zomepirac sodium salt ()
Zomepirac (sodium salt) ()
Zomepirac sodium salt dihydrate ()
Zomepirac sodium anhydrous ()
NSC-757379 ()
Zomaxin ()
Zopirac ()
P&D ID
PD001718
CAS
64092-49-5
64092-48-4
33369-31-2
Tags
natural product
drug
available
Drug indication
Analgesic
Anti-Inflammatory
Pain
Drug Status
approved
withdrawn
Max Phase
Phase 4
First approval
1980
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
18
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
291.07
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
2.85
TPSA
59.3
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Immunology/Inflammation
Target
PDE2
PTGDR2
PGE synthase
MOA
prostaglandin synthesis inhibitor
ATC
M01AB04
Toxicity type
dermatological
Source data
